DocGo (DCGO) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Financial performance and growth

• Achieved over $165 million in Q2 revenue, up 30% year-over-year, with adjusted EBITDA exceeding $17 million and positive net income.

• Cash balance increased from under $60 million to over $85 million, with Q2 cash flow from operations up $25 million.

• Updated 2023 core revenue guidance (excluding migrant contracts) to $280–$300 million, targeting $400 million for 2024.

• Raised 2023 cash flow from operations guidance to $80–$90 million.

• Active share repurchase program with $10 million bought back YTD and $26 million authorized for the remainder of the year.

Business segments and customer channels

• Medical transportation is a $200 million run-rate business, about 25% of Q2 revenue, with "Uber for ambulances" model.

• Mobile health represents 70% of reported revenue, but excluding migrant business, transportation and mobile health are roughly equal.

• Migrant-related municipal revenue expected at $300–$350 million in 2023, winding down in 60–90 days, with some medical care possibly extending into 2024.

• 2024 projections: hospital systems $250 million, municipal (ex-migrant) $100 million, payer side $50 million.

• Emphasis shifting from episodic emergency response to longitudinal population health programs for underserved communities.

Strategic direction and pipeline

• Focus on expanding hospital system partnerships, especially in medical transportation and transitions of care.

• Municipal pipeline includes virtual nursing, behavioral health, and mobile X-ray programs in states like New Mexico and Arizona.

• Payer contracts target in-home care gap closure, with 45 clinical offerings and proven reduction in hospital readmissions by 50–60%.

• Pipeline management uses probability-weighted, bottoms-up modeling for revenue forecasting.

• Plans to maintain at least $100 million in cash to demonstrate scalability to large partners.